← Back to patent-cliff list
Trans-resveratrol (Jupiter Orphan Therapeutics)
Tier C — Watch / tradeTrans-resveratrol (Jupiter Orphan Therapeutics)
Jupiter Orphan Therapeutics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SIRT1
Brand：Jotrol, resVida
Indications (approved)：Friedreich's ataxia, Parkinson's disease, Alzheimer's disease
Regional status
US
Phase II
2025-11-05
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Trans-resveratrol (Jupiter Orphan Therapeutics)?
Approved indications include: Friedreich's ataxia, Parkinson's disease, Alzheimer's disease.
When does the Trans-resveratrol (Jupiter Orphan Therapeutics) patent expire?
No public expiry year is available for Trans-resveratrol (Jupiter Orphan Therapeutics) yet; this page updates once verified.
How do I get a quote for Trans-resveratrol (Jupiter Orphan Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30